Anti-BRAF plus an anti-MEK is currently used in first line for the management of patients presenting metastatic melanomas harboring the BRAF V600E mutation. However, the main issue during targeted therapy is the acquisition of cellular resistance in 80% of the patients, which is associated with an increased metastasis due to the hyperactivation of MAP kinase pathway. Previous reports have indicated that Discoidin Domain Receptors (DDRs) 1 and 2 can activate this pathway. To study the role of DDRs in melanoma cell resistance to targeted therapy, we first determined that DDRs are overexpressed in vemurafenib resistant cells compared to sensitive cells. We demonstrated that DDRs depletion or inactivation by DDRs inhibitors such as dasatinib or CR-13542 reduces tumor cell proliferation, due to a decrease of MAP kinase pathway activity in resistant cells. Finally, we confirmed these results in vivo in a xenograft mouse model and show that DDRs could be new therapeutic targets in resistant patients with metastatic melanoma. We propose that dasatinib could be a second-line treatment after the bi-therapy in resistant patients overexpressing DDRs.
Introduction
Melanoma, a malignant transformation of melanocytes, is the most aggressive form of skin cancer (Conde-Perez and Larue 2014). In 2018, it was predicted that there were 287 723 new melanoma cases were diagnosed worldwide and 60 712 deaths (Bray et al. 2018) . Before 2011, the overall survival was six months; however, due to the development of combined targeted therapy and immunotherapy, it is now up to two years Long et al. 2015; Luke et al. 2017) .
The most common type of cutaneous melanoma is Superficial Spreading Melanoma (SSM) which accounts for 70% of all melanomas (Elder et al. 2018) . The BRAF V600E mutation is observed in almost 60% of SSM (Ascierto et al. 2012) . The BRAF gene encodes a protein kinase involved in the MAP kinase pathway. Its mutation induces a constitutive activation of BRAF, leading to over-activation of the downstream signaling pathways, notably MEK and ERK. This in turn promotes anarchic cell proliferation and cell invasion in melanoma (Davies et al. 2002) . During the past few years, therapies such as targeted bi-therapy or more recently immunotherapy have been developed. However, the response rate with immunotherapy is only 15% and a severe toxicity was observed in more than 25% of the patients (Luke et al. 2017 ). The combination of two treatments, an anti-BRAF plus an anti-MEK (vemurafenib and cobimetinib or dabrafenib and trametinib), is currently used as first line treatment in the management of patients with metastatic melanomas harboring the BRAF V600E somatic mutation Long et al. 2015) . Vemurafenib and dabrafenib inhibit the activity of BRAF mutated protein whereas trametinib and cobimetinib inhibit MEK protein expression (Chapman et al. 2011; Flaherty et al. 2012; Hauschild et al. 2012 ). However, the main problem related to targeted therapy is the acquisition of cellular resistance in 80% of the patients, approximately two years after the treatment start (Sullivan and Flaherty 2013) . This resistance is associated with an increased metastasis notably due to a hyperactivation of MAP kinase activity (Sullivan and Flaherty 2013) . The hyperactivation of this signaling pathway could be due to genetic events including NRAS or BRAF mutations (Wagenaar et al. 2014) , splice variation of BRAF, secondary mutation of MEK, overexpression of the oncoprotein BRAF or upregulation of tyrosine kinase receptors such as PDGFR, EGFR or FGFR (Basile et al. 2014; Du and Lovly 2018; Nazarian et al. 2010; Villanueva et al. 2010; Wagenaar et al. 2014 ).
Previous reports have indicated that Discoidin Domain Receptors (DDRs) 1 and 2 can also activate MAP kinase pathway (Chetoui et al. 2011; El Azreq et al. 2016; Ongusaha et al. 2003; Park et al. 2015; Ren et al. 2014; Valiathan et al. 2012a) . DDRs belong to the tyrosine kinase receptor family and are composed of two members, DDR1 and DDR2 (Leitinger 2014) . These transmembrane receptors are activated by collagens in their native triple helix form (Leitinger 2003; Shrivastava et al. 1997; Vogel et al. 1997) . DDR1 is activated for instance by type I and IV collagens whereas DDR2 preferentially binds type I, II and X collagens (Leitinger 2003; Leitinger and Kwan 2006; Shrivastava et al. 1997; Vogel et al. 1997) . Moreover, DDRs are involved in several physiological functions and have been found overexpressed in a large number of cancer subtypes where they are associated with cell proliferation, invasion, migration and drug resistance (Badiola et al. 2011; Das et al. 2006a; Ezzoukhry et al. 2016; Juin et al. 2014; Malaguarnera et al. 2015; Nemoto et al. 1997; Payne and Huang 2014; Rudra-Ganguly et al. 2014; Xiao et al. 2015) . DDR1 is involved in resistance to cancer therapy by activating Cox2 expression through NFκB pathways in breast cancer cells (Das et al. 2006b ). DDR1 also promotes tumor cell resistance in lymphoma, ovarian cancer and glioblastoma cells (Ren et al. 2013, 2) . Overexpression of DDR2 is associated with breast cancer recurrence through activation of the Erk/Snail 2 pathway (Ren et al. 2013, 2) . In a recent study, binding of collagen 1A to integrins and DDR2 was shown to activate the Src-PI3K/Akt-NFκB signaling pathway, allowing the expression of apoptosisinhibiting proteins (Rada et al. 2018) . Thus, cisplatin-induced apoptosis was shown to be inhibited in ovarian cancer cells in vitro and in vivo (Rada et al. 2018) .
The aim of this study is to fully determine whether DDRs could play a role in the resistance to combined therapy in melanoma. Moreover, we investigated if these receptors could be considered as new targets to counter this resistance process.
Here, we show overexpression of DDRs at protein levels in Vemurafenib resistant cell lines as compared to the sensitive ones. This overexpression is associated with an over activation of MAP kinase pathway. We report that depletion or inhibition of DDRs reduces tumor cell proliferation correlated with a decrease of MAP kinase pathway activity in resistant cells in 2D as well as in a 3D spheroid culture. We confirm these results in vivo in a xenograft mouse model and at clinical level in patient samples. Altogether, our data uncover an important role for DDRs in targeted therapy resistance in melanoma, and demonstrate that targeting those receptors could reduce tumor progression.
Results

DDRs are overexpressed in drug-resistant melanoma cells
To investigate whether DDR1 and DDR2 play a role in melanoma resistance, we determined their expression at mRNA and protein levels in melanoma resistant and sensitive cells. We used two pairs of melanoma cell lines: sensitive (229 S and 238 S) and resistant to vemurafenib (229 R and 238 R). The melanoma resistant cell lines derived from the sensitive B-RAF mutated cell lines by repeated vemurafenib treatment (Søndergaard et al. 2010) .
Resistance was maintained by adding vemurafenib to the culture medium at each passage. As mentioned in the introduction, resistance is associated to an hyperactivation of MAP kinase pathway activity. First, we confirmed that MAP kinase is overactivated in resistant cells compared to sensitive cells ( Figure 1A) . Second, there was an increase in DDR2 mRNA level in resistant cells compared to sensitive cells, whereas DDR1 mRNA level increased only in 238 R but not in 229 R cells ( Figure 1B) . In the study by Nazarian et al, DDR1 mRNA level did not increase in the 238 R and 229 R cells . However, at the protein level, we demonstrated that DDR1 and DDR2 are both overexpressed in resistant cells compared to sensitive ones (a 1.5-fold increase for DDR1 in both resistant cells lines whereas a 2-fold increase for DDR2 in 238R and a 6-fold increase in 229R) ( Figure 1C) . The overexpression in resistant cells was higher for DDR2 than for DDR1 compared to sensitive cells ( Figure 1C) .
Currently, melanoma patients are treated with the combination of a bi-therapy, hence, we measured DDRs expression in melanoma sensitive cells treated with vemurafenib, cobimetinib or both during two months. We demonstrated that sensitive cells treated 2 months with the bi-therapy exhibit a DDRs overexpression ( Figure 1D) 
DDRs are involved in MAP kinase pathway activation
In order to test the hypothesis that overactivation of MAP kinase pathway in resistant melanoma cells is due to DDRs overexpression, we analyzed the impact of DDRs depletion or DDRs kinase domain inactivation on this pathway. We quantified the effect of DDRs depletion by siRNA targeting DDR1, DDR2, or both, on MAP kinase pathway activity. We found that DDR1 and/or DDR2 silencing induced a decrease of PErk/Erk ratio in 238 R and 229 R cells (Figure 2A, supplementary figure 1A) . Furthermore, we aimed to confirm this result by studying the impact of DDRs silencing on various MAP kinase targets at mRNA level such as PHLDA1 and ETV4. Indeed, DDR1 and/or DDR2 depletion induced a decrease of mRNA level of most of MAP kinase pathway targets (Figure 2B, supplementary figure   1B ). To confirm these data and to bring this concept closer to a potential clinical use, we searched for FDA-approved drugs that inhibit kinase domains in both DDRs. We selected dasatinib, a multi-tyrosine kinase inhibitor which inhibits DDR1 and DDR2 kinase domains simultaneously at nanomolar range (Day et al. 2008) . Moreover, dasatinib is currently employed in clinical practice for patients with chronic myeloid leukemia (Keating 2017) . We observed that treating 238 R cells with 100 nM dasatinib for 2 hours inhibited, as expected, DDR1 and DDR2 auto-phosphorylation. In parallel, this treatment decreased the PErk/Erk ratio in vemurafenib-resistant melanoma cells (Figure 2C, supplementary figure 1C ). This indicates that the kinase activity of DDRs is important for MAP kinase pathway activity in resistant cells. Altogether, these data demonstrate that DDRs are involved in MAP kinase pathway over-activation in resistant melanoma cell lines.
DDRs are involved in resistant tumor cell proliferation
As DDRs play a role in MAP kinase signaling pathway, we investigated the biological impact of DDRs inhibition on tumor cell proliferation. For this purpose, we analyzed the impact of DDRs silencing or kinase domain inhibition on cell proliferation, monitored in real time using IncuCyte® cell monitoring. First, we demonstrated that when DDR1, DDR2 or both are depleted using siRNA, there is a significant decrease of tumor cell proliferation in both resistant cell lines (Figure 3A, supplementary figure 2A ). We also observed an inhibition of tumor cell proliferation when cells are treated with dasatinib at 100 nM (concentration where DDRs kinase activity is totally inactivated) compared to the control (Figure 3B, supplementary figure 2B) . These results indicate that DDRs are required for cell proliferation in resistant melanoma cell lines. Overexpression of DDR2 is more pronounced than DDR1 in resistant cell lines compared to the sensitive cells ( Figure 1C) , hence, we decided to test the impact of DDR2 inhibition on cell proliferation. We transfected melanoma resistant cells with wild-type DDR2 or DDR2 kinase-dead mutant (K608E mutation, named DDR2 KD). Transfecting cells with DDR2 KD mutant decreased cell proliferation as observed with dasatinib ( Figure 3C, supplementary figure 2C) . These results suggest that the effect observed with dasatinib is due to DDR2 inactivation. Recently, WRG28 was identified as a DDR2 allosteric and selective inhibitor (Grither and Longmore 2018) . WRG28 acts via the extracellular domain of the receptor in an allosteric manner. It is highly selective and can dissociate preformed DDR2 collagen complex, disrupt receptor clustering in solution, inhibit kinase-independent receptor function. Based on this, and to confirm data obtained with the DDR2-KD mutant, we analyzed the impact of this DDR2
inhibitor on cell proliferation. Treatment of melanoma resistant cells with CR-13452, a WRG-28 analog, decreases DDR2 phosphorylation, ERK phosphorylation and consequently, inhibits cell proliferation, confirming the results previously obtained with dasatinib and kinase-dead experiments ( Figure 3D ). In this study, we used several ways to inhibit DDRs such as siRNA, dasatinib and a DDR2 inhibitor. To fully determine the role of DDRs in melanoma resistance to targeted therapy and the relevance of the dasatinib treatment in this context, it is important to investigate the effect of dasatinib in these melanoma resistant cells.
Indeed, dasatinib is known to inhibit several targets such as Abl, DDR1, DDR2, Src. Of course, the Dasatinib impact depends on the concentration. We could observe a low and nonsignificant decrease of P Src expression in Dasatinib condition as compared to the control whereas there is a non-significant increase of P Src activity when treated with DDR2
inhibitor. We do not observe any difference on P Src expression between siControl and siDDR2 (Supplementary Figure 2E) . We demonstrate that at this concentration, dasatinib blocks DDRs thereby decreasing cell proliferation in melanoma resistant cells. In addition to MAP kinase pathway, we analyzed by mass spectrometry the variations in protein expression following treatment of the 238R cells with dasatinib, DDR2 inhibitor or after transfection with siRNA targeting DDR2. By Gene set enrichment analysis (GSEA), we looked for the other commonly deregulated pathways under these 3 conditions showing that RhoA and EIF2 signaling are deregulated (Supplementary figure 3) .
DDRs involvement in resistant tumor progression in 3D
To analyze DDRs role in physiological conditions, we tested the role of DDRs in cell proliferation using a 3D culture of spheroids. The resistant cells seeded in non-adherent conditions have the ability to form spheroids 72 h after seeding. To study the impact of dasatinib on spheroid maintenance, spheroids were treated with dasatinib at 100 nM, 72 h after seeding. We observed a disruption of spheroids only in dasatinib condition (Figure 4A,   Supplementary figure 4A) . A quantification of the spheroid areas demonstrated that this area significantly decreased in the dasatinib condition (Figure 4B, Supplementary figure 4B) . In order to verify whether the decrease in cell proliferation after dasatinib treatment is due to apoptosis, we monitored the Caspase 3/7 activity in 2D, on cells treated with dasatinib or not.
We show that cells that have been treated with dasatinib are apoptotic, suggesting that dasatinib induces cell death in resistant melanoma cell lines (Figure 4C, Supplementary   figure 4C ). In order to validate these results on spheroid maintenance, we treated the spheroids 72 h after their formation with the DDR2 inhibitor CR-13452 (5 µM). Once again, we demonstrate that DDR2 inhibition led to an alteration of spheroid maintenance and to a decrease of its area ( Figure 4D&E ). We confirmed that cells that have been treated with DDR2 inhibitor are apoptotic in 2D, suggesting that DDR2 inhibitor induces cell death in resistant melanoma cell lines ( Figure 4F) .
Altogether, these data strongly suggest that DDRs are an important target in melanoma resistant cell proliferation and that they can be targeted by dasatinib or DDR2 inhibitor.
Role of DDRs in resistant tumor progression in vivo
An in vivo validation of the dasatinib effect is necessary to fully confirm its potential to target DDRs in melanoma cells resistant to vemurafenib. For that, we tested impact of dasatinib in vivo, in a xenograft mouse model of melanoma resistant cells. First, we subcutaneously implanted 229 R cells in NSG mice. When tumors reached 150 mm 3 , animals were separated in two groups: one group treated with dasatinib and a control group still treated with vemurafenib by oral gavage (Figure 5A) . When mice were treated with dasatinib, we observed a stabilization of tumor growth compared to the control group treated with vemurafenib, in which tumor growth dramatically increased (Figure 5B & C) . A western blot analysis of mice tumors treated with dasatinib showed a decrease in DDR1 and DDR2 phosphorylation activity, as compared to a control mouse treated with vemurafenib ( Figure   5D ). These results indicate that dasatinib inhibited both DDR1 and 2 phosphorylation in vivo.
Furthermore, we analyzed and compared tissue sections from mice tumor treated with dasatinib or vemurafenib. We observed necrotic areas in dasatinib treated mice compared to mice treated with vemurafenib ( Figure 5E ). We confirmed this result by Annexin V labeling, which is found in necrotic areas of dasatinib treated tumors (Figure 5E ). This result is consistent with data obtained with spheroids (Figure 4) . These results demonstrate that dasatinib has a pro-apoptotic activity in mice subcutaneously implanted with melanoma vemurafenib resistant cells. In order to evaluate the clinical relevance of our results, we analyzed RNA sequencing database from 21 patients before and after treatment to dabrafenib which is an anti-BRAF. The data are provided from Gene Expression Omnibus (accession number: GSE50509). We studied abundance of DDR1, DDR2 or both, before and after treatment with dabrafenib. Following dabrafenib treatment, DDR1 is overexpressed in 38% of the cases, while DDR2 is overexpressed in 24% of the cases. Moreover, very importantly, we observed an overexpression of DDR1, DDR2, or both in 80% of the cases (Figure 5F ). All these findings correlate with our in vitro data and highlight that DDR1 and DDR2 could be new therapeutic targets in patients with metastatic melanoma resistant to anti-BRAF therapies. Dasatinib could then be clinically used in resistant patients following targeted dual therapy and who are not included in an immunotherapy protocol.
Discussion
When patients develop metastatic melanoma harboring the BRAF V600E mutation, the first line of treatment corresponds to a targeted bi-therapy with anti-BRAF and anti-MEK.
However, 80% of the cases become resistant to this treatment, approximatively after 2 years Long et al. 2015) . Resistance to BRAF in melanoma leads to an over-activation of MAP kinase pathway which could be due to different alterations, either genetic or epigenetic, including overexpression of tyrosine kinase receptors such as PDGFR or EGFR Sullivan and Flaherty 2013 (Deng et al. 2017a ). It could be then interesting to study if there is any DDR1 regulation by microRNA in melanoma resistant cells. However, DDR2 seems to be more overexpressed than DDR1 in melanoma resistant cells compared to the sensitive cells. It could maybe due to the fact that melanoma resistant cells secreted their own matrix.
Indeed, we demonstrated in our lab, that DDR1 expression is reduced when the cells are seeded on collagen I, whereas Sekiya et al showed that, in stellar hepatic cells, DDR2 mRNA can be decreased by microRNA-29b, which targets collagen I, suggesting a relationship between collagen I expression and DDR2 (Sekiya et al. 2011 ). Furthermore, as the microenvironment plays a critical role in melanoma resistance to vemurafenib, it would be then interesting to study DDRs expression in stromal cells (Chetoui et al. 2011; El Azreq et al. 2016; Ongusaha et al. 2003; Park et al. 2015; Ren et al. 2014; Valiathan et al. 2012a ); DDR1 and DDR2 expression was observed in stromal cells in other cancers promoting cell invasion and metastasis formation (Corsa et al. 2016; Gonzalez et al. 2017; Jin et al. 2018) . At the clinical level, we found that abundance of DDR1, DDR2 or both increases after treatment to an anti-BRAF, confirming the results obtained in vitro.
DDRs are major players in cancer progression and are associated with a bad prognosis when overexpressed (Henriet et al. 2018; Valiathan et al. 2012a We demonstrated that DDRs depletion reduced tumoral cell proliferation by reducing MAP kinase pathway activity. To test its clinical relevance, we selected dasatinib, an FDAapproved kinase domain inhibitor in chronic myeloid leukemia (Keating 2017) . Dasatinib is also known as an inhibitor of SRC, which is engaged in a regulatory loop with DDRs (Day et al. 2008) . We demonstrated that DDRs inactivation by dasatinib inhibits melanoma cell proliferation in vitro. As DDR2 is five-times more overexpressed than DDR1 in resistant cells compared to sensitives cells, we focused on this receptor first. DDR2 acts as a major player of tumor progression, migration and proliferation in melanoma (Badiola et al. 2011; Poudel, Lee, and Kim 2015) . We confirmed results obtained with dasatinib, by using a DDR2 kinase-dead mutant and a selective DDR2 inhibitor. All promoted a decrease of tumoral cell proliferation suggesting that effect observed with dasatinib is mainly due to DDR2. Furthermore, by proteomic analysis, we demonstrated that DDR2 depletion with siRNA, DDR2 selective inhibition or Dasatinib treatment induce a decrease of RhoA signaling. Thoese results confirmed the recent study of Misek et al, which showed that in resistant cells there is an accumulation of actin stress fiber due to RhoA activation (Misek et al. 2019) .
We demonstrated that inactivation of DDRs, or specifically DDR2 inhibition, promotes alteration of the spheroid maintenance by disruption of the cells (in 3D) and inducing cell apoptosis (in 2D). It could be relevant to study DDRs localization in these conditions as DDR1 is known to play a role in cell-cell junctions whereas there has been no reports on this role for DDR2 (Hidalgo-Carcedo et al. 2011) . Indeed, DDRs can be present in various subcellular compartments associated with several cellular processes involved in cancer progression (Henriet et al. 2018) . For example, DDR1 and DDR2 co-localize along the same fiber of collagen I (Henriet et al. 2018) .
To confirm our result in vivo, we validated dasatinib effect in a xenograft mouse model and observed that dasatinib blocks tumor proliferation of vemurafenib-resistant melanoma cells.
Sequential treatment is a crucial question in clinic to abrogate the toxicity due to therapy combination or to alternate treatments (Wang et al. 2018) . Currently, a study demonstrated that switching from MAPK inhibitor therapy to vorinostat, is more effective in eradicating drug-resistant cells than a drug holiday (Wang et al. 2018) . In this respect, we could study the effect of sequential treatment, in long term, in order to delay the apparition of resistance to vemurafenib or dasatinib (Wang et al. 2018) .
We demonstrated that DDRs could be a good target in melanoma resistance to targeted therapy. DDRs may be targeted using FDA-approved tyrosine kinase receptor inhibitors such as dasatinib, imatinib, nilotinib with an IC50 in the low nanomolar range (Day et al. 2008) .
Nilotinib and dasatinib are more potent than imatinib toward DDR1 and DDR2 (Day et al. 2008 
Reagents and drugs
Collagen polymerization was carried out as described previously (Juin et al., 2012) . In brief, collagen was diluted at 0.5 mg/ml in DPBS 1X, then polymerized for 4 h at 37 °C before cell seeding. Cells were seeded for 4 h on collagen before fixation.
Vemurafenib and dasatinib were purchased from LC laboratories. DDR2 inhibitor (CR-13452) was a generous gift from Pr. Gregory Longmore Lab.
Western Blot
Protein cell lysates were obtained in radio-immunoprecipitation assay buffer ( Then, we monitored spheroid formation using IncuCyte® videomicroscopy for 72 h. After spheroid formation, the treatment (dasatinib or CR-13452) was added. The quantifications of spheroid area and perimeter were performed using Image J.
RT-qPCR
Proteomic analysis
Cell lysis was performed in RIPA Buffer. The steps of sample preparation and protein digestion were performed as previously described (Henriet et al. 2017 Proteins identification was accepted only with at least 2 specific peptides with a pretty rank=1 and with a protein FDR value less than 1.0% calculated using the "decoy" option in Mascot.
Label-free quantification of MS1 level by extracted ion chromatograms (XIC) was carried out with parameters indicated previously (Henriet et al. 2017) . Protein ratios were median normalized.
Gene Set Enrichment Analysis was performed against the Ingenuity Pathways Database (Canonical Pathways). Only commonly and significantly deregulated pathways were considered.
Xenograft mouse model
The institutional animal ethics committee of Bordeaux University approved all animal use procedures and all efforts were made to minimize animal suffering. Five million 229 R cells were resuspended in a mixed 1:1 with DMEM 4.5 g/l glucose Glutamax-I medium and matrigel. The mixture was then injected subcutaneously into the right flank of anesthetized 8 weeks-old NOD/LtSz-scid IL2Rγnull (NSG) mouse. Tumor formation and tumor volume, based on caliper measurements, were monitored twice a week. The mice were treated with vemurafenib. until the tumors reached approximately 150 mm 3 in volume. Subsequently, the mice were randomly assigned in 2 groups: one control group where mice were treated with vemurafenib (40 mg/kg) by oral gavage, and one group where mice were treated with dasatinib (20 mg/kg) by oral gavage (n=5 in each condition).
Immunohistochemistry
Primary tumors were fixed in 10% buffered formaldehyde. Selected representative slides including treated tumors with dasatinib or not treated tumors were processed for Annexin V immunohistochemistry (IHC). The 2.5 μm thick sections were dewaxed and rehydrated and antigen was retrieved in a sodium citrate buffer (pH6 solution for 20 mins).
All staining procedures were performed in an automated autostainer (Dako-Agilent Clara, United States) using standard reagents provided by the manufacturer. The sections were incubated with an anti-Annexin V (Abcam, ab14196) rabbit polyclonal antibody (16210-1-AP; ProteinTech) at a 1µg/ml dilution for 45 min at room temperature. EnVision Flex/HRP (Horseradish peroxidase) (Dako-Agilent, 20 minutes) was used for signal amplification. 3,3'-Diamino-benzidine (DAB, Dako) development was used for detecting primary antibodies.
The slides were counterstained with hematoxylin, dehydrated and mounted. Each immunohistochemical run contained a negative control (buffer, no primary antibody).
Sections were visualized with a Nikon-Eclipse501 microscope, and images were acquired using NIS-Elements F.
Statistical Analysis
Data were reported as the mean ± SEM of at least three experiments. Statistical analyses were performed using GraphPad Prism 5.0. The differential protein expression between the cell lines was validated by a t test * p<0.05. One-way ANOVA analysis of variance followed by Bonferroni post-test was used for the comparison of means in experiments containing three groups or more * P0.05, ** P≤0.01, *** P≤0.001.
Data availability section
RNA seq data: gene expression Omnibus GSE50509 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50509) Values are expressed as the mean ± SEM of three independent experiments. The differential expression between the control and the different conditions was validated by a paired t test *P<0.05, ***P<0.001. C) 238R were treated with dasatinib during 2 hours. Protein extract were then analyzed by immunoblotting to determine PErk, Erk, DDR1 and DDDR2 expression. GAPDH was used as the endogenous loading control. The graph shows the quantification of the ratio of PDDR1/DDR1, PDDR2/DDR2 and PErk/Erk. Values are expressed as the mean ± SEM of three independent experiments. The differential expression between the conditions was validated by a paired t test **P<0.01.
Figures Legends
Figure 3: DDRs role in proliferation
A) Incucyte proliferation assay of 238R cells seeded at 5 000 cells per well in a 96 well plate. The cells were transfected with a siRNA control (siGl2) or targeting DDR1 (siDDR1), DDR2 (siDDR2) or both (siDDR1&2). The differential proliferation between the control and the different conditions was validated by a paired t test *P<0.05. B) Incucyte proliferation assay of 238R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of 100 nM dasatinib. The differential proliferation between the control and the different conditions was validated by a paired t test **P<0.01. C) Proliferation of 229 R cells seeded at 5 000 cells per well in a 96 well plate. The cells were transfected with DDR2 WTmyc or DDR2 KD(K608E)-myc. The differential proliferation between the control and different conditions was validated by a paired t test *P<0.05. Protein extracts were then analyzed by immunoblotting to determine DDR2-myc expression. GAPDH was used as the endogenous loading control. D) Incucyte proliferation assay of 229R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of DDR2 inhibitor. The differential proliferation between the control and different conditions was validated by a paired t test *P<0.05, **P<0.01, ***P<0.001. Protein extracts were then analyzed by immunoblotting to determine P DDR2, DDR2, P Erk, Erk expression. GAPDH was used as the endogenous loading control. The graph shows the quantification of the ratio of PDDR2/DDR2 and PErk/Erk. Values are expressed as the mean ± SEM of three independent experiments. The differential expression between the conditions was validated by a paired t test ***P<0.001.
Figure 4: DDRs role in spheroid maintenance
A) 238 R cells were seeded to form spheroids and spheroid at 72 hours were treated with Dasatinib at 100 nM. B) The graph shows the quantification of the area in the different conditions. Values are expressed as the mean ± SEM of three independent experiments. The differential area quantification was validated by a paired t test *P<0.05. C) Incucyte apoptotic assay of 238R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of dasatinib (100 nM). The differential proliferation between the different conditions was validated by a paired t test *P<0.05. D) The Spheroids at 72 hours were treated with DDR2 inhibitor at 5 µM. E) The graph shows the quantification of the area in the different conditions. Values are expressed as the mean ± SEM of three independent experiments. The differential area was validated by a paired t test **P<0.01. F) Incucyte apoptotic assay of 229R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of DDR2 inhibitor (5 µM). The differential proliferation between the different conditions was validated by a paired t test **P<0.01. abundance after treatment to an anti-BRAF. All the dots above the black lines, meaning that there is an increase of receptor's abundance after treatment (in grey if DDR1 is overexpressed, in blue if DDR2 is overexpressed, in red if DDR1 and 2 are overexpressed).
Supplementary figure 1: DDRs role in MAP kinase pathway.
A) 229R cells were transfected with a siRNA control (siGl2) or targeting DDR1 (siDDR1), DDR2 (siDDR2) or both (siDDR1&2). Protein extracts were then analyzed by immunoblotting to determine PErk and Erk expression. GAPDH was used as the endogenous loading control. B) mRNA level of MAP kinase targets in 229 resistant (R) to vemurafenib. The graph shows the quantification of PHLDA1, SPRY2, DUSP6, DUSP4, ETV4, ETV5 expression. Values are expressed as the mean ± SEM of three independent experiments. The differential mRNA level between the control and different conditions was validated by a paired t test *P<0.05. C) 229R were treated with dasatinib during 2 hours. Protein extract were then analyzed by immunoblotting to determine PErk and Erk expression. GAPDH was used as the endogenous loading control. The graph shows the quantification of the ratio of PDDR1/DDR1, PDDR2/DDR2 and PErk/Erk. Values are expressed as the mean ± SEM of three independent experiments. The differential expression between the conditions was validated by a paired t test *P<0.05, **P<0.01.
Supplementary figure 2: DDRs role in proliferation A)
Incucyte proliferation assay of 229 R cells seeded at 5 000 cells per well in a 96 well plate. The cells were transfected with a siRNA control (sGl2) or targeting DDR1 (siDDR1), DDR2 (siDDR2) or both (siDDR1&2). The differential proliferation between the different conditions was validated by a paired t test *P<0.05. B) Incucyte proliferation assay of 229R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of 100 nM dasatinib. The differential proliferation between the control and the different conditions was validated by a paired t test **P<0.01. C) Proliferation of 238R cells seeded at 5 000 cells per well in a 96 well plate. The cells were transfected with DDR2 WT-myc or DDR2 KD(K608E)-myc. The differential proliferation between the control and the different conditions was validated by one-way ANOVA *P<0.05. D) Incucyte proliferation assay of 238R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of DDR2 inhibitor. The differential proliferation between the control and the different conditions was validated by a one-way ANOVA *P<0.05. E) 238R were transfected with a siRNA control (siCtrl) or targeting DDR2 (siDDR2) or treated with DDR2 inhibitor during 72 hours. 238R cells were treated with dasatinib during 2 hours. Protein extract were then analyzed by immunoblotting to determine PErk, Erk, PAkt and Akt expression. Protein extracts were analyzed by immunoblotting to determine P DDR2, DDR2, P Src, Src expression. GAPDH was used as the endogenous loading control. The graph shows the quantification of the ratio of PSrc/Src. Values are expressed as the mean ± SEM of three independent experiments. The differential expression between the conditions was validated by a one-way ANOVA or a paired t test: ns: non-significant.
Supplementary figure 3: GSEA analysis
Pathways commonly and significantly enriched between the following conditions: 238R cells treated with dasatinib, with a DDR inhibitor or transfected with siRNA targeting DDR2. Gene set enrichment analysis (GSEA) was performed against the Ingenuity Pathways database (fisher test expressed in -log10pvalue).
Supplementary figure 4: DDRs role in spheroid maintenance in 229R
A) 229 R cells were seeded to form spheroids and spheroid at 72 h were treated with dasatinib at 100 nM. B) The graph shows the quantification of the area in the different conditions. Values are expressed as the mean ± SEM of three independent experiments. The differential expression was validated by a paired t test ***P<0.001. C) Incucyte apoptotic assay of 229R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of dasatinib (100 nM). The differential proliferation between the different conditions was validated by a paired t test *P<0.05. Values are expressed as the mean ± SEM of three independent experiments. The differential expression between the cell lines was validated by a t test *P<0,05. D) Western blotting analysis of DDR1 and DDR2 expression in a 229 sensitives cell lines treated with Vemurafenib (10 nM), Cobimetinib (10 nM) or both during 2 months. GAPDH was used as the endogenous loading control. Incucyte proliferation assay of 238R cells seeded at 5 000 cells per well in a 96 well plate. The cells were transfected with a siRNA control (siGl2) or targeting DDR1 (siDDR1), DDR2 (siDDR2) or both (siDDR1&2). The differential proliferation between the control and the different conditions was validated by a paired t test *P<0,05. B) Incucyte proliferation assay of 238R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of 100 nM Dasatinib. The differential proliferation between the control and the different conditions was validated by a paired t test **P<0,01. C) Proliferation of 229 R cells seeded at 5 000 cells per well in a 96 well plate. The cells were transfected with DDR2 WT-myc or DDR2 KD(K608E)-myc. The differential proliferation between the control and different conditions was validated by a paired t test *P<0,05. Protein extracts were then analysed by immunoblotting to determine DDR2-myc expression. GAPDH was used as the endogenous loading control. D) Incucyte proliferation assay of 229R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of DDR2 inhibitor. The differential proliferation between the control and different conditions was validated by a paired t test *P<0,05, **P<0,01, ***P<0,001. Protein extracts were then analysed by immunoblotting to determine P DDR2, DDR2, P Erk, Erk expression. GAPDH was used as the endogenous loading control. The graph shows the quantification of the ratio of PDDR2/DDR2 and PErk/Erk. Values are expressed as the mean ± SEM of three independent experiments. The differential expression between the conditions was validated by a paired t test ***P<0,001. shows the quantification of the area in the different conditions. Values are expressed as the mean ± SEM of three independent experiments. The differential area quantification was validated by a paired t test *P<0,05. C) Incucyte apoptotic assay of 238R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of Dasatinib (100 nM). The differential proliferation between the different conditions was validated by a paired t test *P<0,05. D) The Spheroids at 72 hours were treated with DDR2 inhibitor at 5 µM. E) The graph shows the quantification of the area in the different conditions. Values are expressed as the mean ± SEM of three independent experiments. The differential area was validated by a paired t test **P<0,01. F) Incucyte apoptotic assay of 229R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of DDR2 inhibitor (5 µM). The differential proliferation between the different conditions was validated by a paired t test **P<0,01. abundance after treatment to an anti-BRAF. All the dots above the black lines, meaning that there is an increase of receptor's abundance after treatment (in grey if DDR1 is overexpressed, in blue if DDR2 is overexpressed, in red if DDR1 and 2 are overexpressed). Incucyte proliferation assay of 229 R cells seeded at 5 000 cells per well in a 96 well plate. The cells were transfected with a siRNA control (sGl2) or targeting DDR1 (siDDR1), DDR2 (siDDR2) or both (siDDR1&2). The differential proliferation between the different conditions was validated by a paired t test *P<0,05. B) Incucyte proliferation assay of 229R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of 100 nM Dasatinib. The differential proliferation between the control and the different conditions was validated by a paired t test **P<0,01. C) Proliferation of 238R cells seeded at 5 000 cells per well in a 96 well plate. The cells were transfected with DDR2 WT-myc or DDR2 KD(K608E)-myc. The differential proliferation between the control and the different conditions was validated by one way anova *P<0,05. D) Incucyte proliferation assay of 238R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of DDR2 inhibitor. The differential proliferation between the control and the different conditions was validated by a one way anova *P<0,05. E) 238R were transfected with a siRNA control (siCtrl) or targeting DDR2 (siDDR2) or treated with DDR2 inhibitor during 72 hours. 238R cells were treated with Dasatinib during 2 hours. Protein extract were then analysed by immunoblotting to determine PErk, Erk, PAkt and Akt expression. Protein extracts were analysed by immunoblotting to determine P DDR2, DDR2, P Src, Src expression. GAPDH was used as the endogenous loading control. The graph shows the quantification of the ratio of PSrc/Src. Values are expressed as the mean ± SEM of three independent experiments. The differential expression between the conditions was validated by a one way anova or a paired t test: ns: non significant. 100 nM. B) The graph shows the quantification of the area in the different conditions. Values are expressed as the mean ± SEM of three independent experiments. The differential expression was validated by a paired t test ***P<0,001. C) Incucyte apoptotic assay of 229R cells seeded at 5 000 cells per well in a 96 well plate cultured in the presence or absence of Dasatinib (100 nM). The differential proliferation between the different conditions was validated by a paired t test *P<0,05. 
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